Meyers Michael L. 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 3, 2022
Insider Transaction Report
Form 4
Meyers Michael L.
SVP, Chief Development Officer
Transactions
- Other
Common Stock
2022-01-31$12.39/sh+1,714$21,236→ 23,280 total - Award
Stock Options (Right to buy)
2022-02-02$15.79/sh+17,350$273,957→ 17,350 totalExercise: $15.79Exp: 2032-02-02→ Common Stock (17,350 underlying)
Footnotes (2)
- [F1]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan.
- [F2]1/23rd of the shares subject to the option shall vest monthly over a two-year period.